Go to the list of all blogs
Allana's Avatar
published in Blogs
Jun 25, 2026
Why Is Aquestive Therapeutics (AQST) Stock Down -14% Today?

Why Is Aquestive Therapeutics (AQST) Stock Down -14% Today?

Key Takeaways

  • AQST shares fell sharply by 14.33% in early trading on elevated volume.
  • No single company-specific catalyst was immediately apparent for the decline.
  • The move occurred amid broader weakness in small-cap biotech and specialty pharma names.
  • Recent company developments, including Q1 results and debt refinancing, had previously supported the stock.
  • Traders are monitoring upcoming regulatory updates for Anaphylm and the next earnings release scheduled for August.

Opening Summary

Aquestive Therapeutics, Inc. develops and commercializes innovative pharmaceutical products using its proprietary PharmFilm technology, focusing on central nervous system disorders and other therapeutic areas. On June 25, 2026, with the market open, AQST shares traded at $4.2750, down 14.33% from the prior session's close of $4.9900. The decline reflects selling pressure without an immediate identifiable news trigger, as the stock pulled back from recent gains.

Market Reaction and Volume

Trading volume exceeded the average, indicating heightened investor activity. The selloff aligned with softer sentiment across select small-cap healthcare peers, though major indices showed mixed performance. Technical levels near recent support were tested as the price moved lower intraday.

Broader Sector and Market Context

The drop took place against a backdrop of variable performance in the specialty pharmaceuticals sector. While AQST had benefited earlier from positive clinical and financing updates, today's action appeared driven more by profit-taking and general risk-off flows in smaller biotech and pharma names rather than any fundamental shift in the company's outlook.

Trending AI Robots

Tickeron’s Trending AI Robots page highlights the strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with only the top performers featured in this curated section. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade. Investors seeking automated trading insights can explore the platform for additional tools and strategies.

What Comes Next for AQST

Investors will watch for regulatory progress on the Anaphylm sublingual film NDA resubmission targeted for the third quarter. The company is also expected to report second-quarter results around August 11. Key risks include clinical development timelines, regulatory decisions, and ongoing cash burn typical of development-stage biopharma firms. Market participants will continue to assess sector sentiment and any new corporate announcements.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AQST

AQST in downward trend: price may drop because broke its higher Bollinger Band on June 17, 2026

AQST broke above its upper Bollinger Band on June 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 41 similar instances where the stock broke above the upper band. In of the 41 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for AQST moved out of overbought territory on June 25, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on June 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AQST as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for AQST turned negative on June 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AQST declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

AQST moved above its 50-day moving average on July 06, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for AQST crossed bullishly above the 50-day moving average on June 18, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AQST advanced for three days, in of 253 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 186 cases where AQST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (46.452). P/E Ratio (0.000) is within average values for comparable stocks, (99.681). AQST's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.697). AQST has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.035). P/S Ratio (9.597) is also within normal values, averaging (114.852).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AQST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AQST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.05B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -3%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 17%. TLPH experienced the highest price growth at 27%, while BTAI experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 5%. For the same stocks of the Industry, the average monthly volume growth was -25% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 66
Price Growth Rating: 55
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 5 (-100 ... +100)
View a ticker or compare two or three
AQST
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer thin film pharmaceutical and over the counter drug products

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Pharmaceuticals Major
Address
30 Technology Drive
Phone
+1 908 941-1900
Employees
147
Web
https://www.aquestive.com
Interact to see
Advertisement
Ondas Holdings (ONDS) is a wireless technology company focused on delivering secure, long-range communications for industrial Internet of Things (IoT) and data networking applications. Its solutions are built to support mission-critical operations across sectors such as rail, energy, maritime, infrastructure, and industrial automation.
Ciena’s growth is driven by expanding offerings in optical networking, network automation software, and 5G transport infrastructure, complemented by services designed to help customers modernize and future-proof their networks. Its evolving technology portfolio addresses the rising complexity, speed, and reliability requirements of today’s communications environment.
MP Materials Corp. (MP) and USA Rare Earth, Inc. (USAR) are central to the United States’ push to establish a secure, domestic supply of rare earth elements—materials critical to electric vehicles, renewable energy, and defense technologies. As geopolitical tensions and supply chain vulnerabilities intensify, these two companies offer distinct approaches to addressing U.S. dependence on foreign sources.
An AI-driven comparison between Palantir (PLTR) and Oracle (ORCL) points to Palantir as the more compelling investment heading into 2026. The analysis highlights PLTR’s AI-native platforms, which enable real-time, data-driven decision-making across fast-growing sectors such as government, defense, and enterprise analytics.
An AI-driven comparison between D-Wave Quantum (QBTS) and IonQ (IONQ) points to IonQ as the stronger opportunity heading into 2026. The analysis highlights IONQ’s gate-based, trapped-ion quantum architecture, which supports a wide range of algorithms and positions the company for broader adoption across AI, simulation, and cryptography.
An AI-driven comparison of Rigetti Computing (RGTI) and D-Wave Quantum (QBTS) points to Rigetti as the more compelling opportunity heading into 2026. The analysis highlights RGTI’s gate-based quantum architecture, which supports universal quantum computing and a wide range of complex algorithms. While D-Wave remains a leader in quantum annealing for optimization problems, Rigetti’s full-stack, gate-based approach offers greater scalability and broader long-term applications.
An AI-driven comparison of Rigetti Computing (RGTI) and TeraWulf (WULF) points to TeraWulf as the more attractive investment heading into 2026. The analysis emphasizes WULF’s large-scale digital infrastructure supporting Bitcoin mining and high-performance computing (HPC), which generates immediate revenue in expanding digital asset and AI-driven markets.
An AI-driven comparison between Rocket Lab USA (RKLB) and Planet Labs (PL) identifies Rocket Lab as the more compelling investment heading into 2026. The analysis highlights RKLB’s vertically integrated space services and consistent launch performance, which position the company to benefit from rising demand for satellite deployment and space infrastructure.
An AI-driven comparison of Tempus AI (TEM) and Doximity (DOCS) points to Tempus AI as the more compelling investment opportunity heading into 2026. The analysis highlights TEM’s AI-powered precision medicine platform, which applies advanced analytics and genomic data to transform diagnostics and treatment in oncology and cardiology.
An AI-driven comparison of UnitedHealth Group (UNH) and CVS Health (CVS) points to UnitedHealth as the stronger investment heading into 2026. The analysis emphasizes UNH’s deeply integrated healthcare model, combining insurance, data analytics, pharmacy services, and care delivery into a single ecosystem. This structure provides resilience and earnings stability in an increasingly complex healthcare environment.
An AI-driven comparison of Netflix (NFLX) and Disney (DIS) points to Netflix as the more attractive investment heading into 2026. The analysis emphasizes Netflix’s focused, pure-play streaming model and its continued investment in original content, which support strong subscriber engagement as viewing habits shift further toward digital platforms.
An AI-driven comparison of Coca-Cola (KO) and PepsiCo (PEP) points to PepsiCo as the more compelling investment for 2026. The analysis emphasizes PepsiCo’s diversified business model, which combines beverages with a broad snack portfolio and provides greater resilience as consumer preferences evolve.
An AI-driven comparison of Philip Morris (PM) and British American Tobacco (BTI) points to Philip Morris as the more attractive investment for 2026. The analysis highlights PM’s accelerated transition toward smoke-free products, which positions the company for sustainable growth as global regulations continue to pressure traditional combustible tobacco.
SoundThinking, Inc. (SSTI), a developer of precision-policing and security technologies, has faced a difficult trading environment in recent weeks. With shares trading in the single digits, the stock reflects broader investor hesitation toward small-cap tech amid ongoing economic uncertainty. The company’s market capitalization stands near $100 million, and its valuation metrics suggest skepticism around its growth outlook.
Lionheart Holdings (CUB) has traded quietly in recent sessions, reflecting the typical behavior of a SPAC still in its pre-merger search phase. Shares have hovered close to the company’s IPO price, supported by low volatility and thin trading volumes. This pattern mirrors broader trends across the SPAC market, where investor engagement often remains subdued until a definitive acquisition agreement is announced.
Astronics Corporation has delivered solid share price performance in recent sessions, benefiting from renewed enthusiasm for aerospace and defense equities. The stock has demonstrated resilience despite broader market volatility, drawing consistent investor interest due to its exposure to mission-critical avionics, power systems, and test equipment.
Recent analyst upgrades from Piper Sandler and Morgan Stanley underscore improving valuation and renewed confidence in Motorola Solutions’ growth outlook. Third-quarter 2025 results exceeded expectations, with revenue increasing 7.8% year over year, driven by land mobile radio (LMR) and video security demand.
General Dynamics shares have remained resilient in recent sessions, continuing an upward trend despite broader market volatility. Heightened attention on global defense spending has reinforced confidence in the company’s extensive backlog and well-balanced exposure across aerospace, marine systems, combat platforms, and mission-critical technologies.
Innovative Aerosystems (ISSC) has emerged as a standout performer within the aerospace and avionics space, with its stock reflecting optimism around rising demand for advanced cockpit and navigation systems. Recent trading has seen shares hold near the upper end of their range, supported by strong fundamentals and a diversified customer base spanning business aviation, commercial airlines, and military platforms.
Hexcel Corporation (HXL), a leading supplier of advanced composite materials used across aerospace, defense, and industrial markets, has maintained steady momentum amid a shifting industry backdrop. Recent share performance reflects investor optimism around a gradual recovery in commercial aviation, balanced against concerns about production timing and cost pressures.